
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Aura Biosciences, Inc.

(Name of Issuer)

Common Stock, \$0.00001 par value per share

(Title of Class of Securities)

05153U107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1 Frazier Life Sciences Public Fund, L.P.

Check the appropriate box if a member of a Group (see instructions)

- 2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	3,113,550.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	3,113,550.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,113,550.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	5.0 %
12	Type of Reporting Person (See Instructions)
	PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

1	Names of Reporting Persons
	FHMLSP, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	Sole Voting Power
5	0.00
	Shared Voting Power
6	3,113,550.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	

3,113,550.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

3,113,550.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

5.0 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

FHMLSP, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

3,113,550.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

3,113,550.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

3,113,550.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

5.0 %

Type of Reporting Person (See Instructions)

12

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

1	Names of Reporting Persons
	Frazier Life Sciences Public Overage Fund, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	918,510.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	918,510.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	918,510.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
	Percent of class represented by amount in row (9)
11	1.5 %
	Type of Reporting Person (See Instructions)
12	PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

Names of Reporting Persons

1

FHMLSP Overage, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

918,510.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

918,510.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

918,510.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

1.5 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

Names of Reporting Persons

1

FHMLSP Overage, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

918,510.00

Beneficially
Owned by

Sole Dispositive Power

Each

7

0.00

Reporting
Person

Shared Dispositive

With:

8

Power

918,510.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

918,510.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



Percent of class represented by amount in row (9)

11

1.5 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

Frazier Life Sciences X, L.P.

Check the appropriate box if a member of a Group (see instructions)

2



(a)



(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of
Shares

5

0.00

Beneficially
Owned by

Shared Voting Power

Each

6

128,520.00

Reporting
Person

Sole Dispositive Power

With:

7

0.00

8

Shared Dispositive

Power

128,520.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

128,520.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

FHMLS X, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

128,520.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

128,520.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

128,520.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

12 Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

FHMLS X, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of Shares

Shared Voting Power

6

128,520.00

Beneficially Owned by

Sole Dispositive Power

Each

7

0.00

Reporting Person

With:

Shared Dispositive

8

Power

128,520.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

128,520.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

Frazier Life Sciences XI, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by

342,210.00

Each

Sole Dispositive Power

7

Reporting

0.00

Person

With:

Shared Dispositive

8

Power

342,210.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

342,210.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.6 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

FHMLS XI, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 342,210.00

Sole Dispositive Power

7 0.00

8 Shared Dispositive Power

342,210.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

342,210.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 0.6 %

Type of Reporting Person (See Instructions)

12 PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1 FHMLS XI, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2 (a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 342,210.00

7 Sole Dispositive Power

0.00
Shared Dispositive
8 Power

342,210.00

Aggregate Amount Beneficially Owned by Each Reporting Person

342,210.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

0.6 %

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

Frazier Life Sciences XII, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Sole Voting Power

5

0.00

Shared Voting Power

6

597,210.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

597,210.00

Aggregate Amount Beneficially Owned by Each Reporting Person

597,210.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

1.0 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

FHMLS XII, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

Beneficially
Owned by

6

597,210.00

Each
Reporting

7

Sole Dispositive Power

Person
With:

0.00

Shared Dispositive

8

Power

597,210.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

597,210.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

1.0 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

FHMLS XII, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by

597,210.00

Each
Reporting

Sole Dispositive Power

7

Person

0.00

With:

Shared Dispositive

8

Power

597,210.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

597,210.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

1.0 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

James N. Topper

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 UNITED STATES

Sole Voting Power

5

0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6

128,520.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

128,520.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 128,520.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 0.2 %

Type of Reporting Person (See Instructions)

12 IN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1 Patrick J. Heron

Check the appropriate box if a member of a Group (see instructions)

2 (a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 UNITED STATES

Sole Voting Power

5

0.00

Number of Shares Beneficially Owned by Each

6 Shared Voting Power

Reporting Person With: 128,520.00
 Sole Dispositive Power
 7
 0.00
 Shared Dispositive Power
 8
 128,520.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

128,520.00
 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)

0.2 %

12 Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.

SCHEDULE 13G

CUSIP No. 05153U107

1 Names of Reporting Persons

Albert Cha
 Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only
 4 Citizenship or Place of Organization

UNITED STATES

Sole Voting Power
 5
 0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 6
 Shared Voting Power
 0.00

Sole Dispositive Power
 7
 0.00

Shared Dispositive Power
 8
 0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

0.00
 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

11

0.0 %

Type of Reporting Person (See Instructions)

12

IN

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

James Brush

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

0.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



Percent of class represented by amount in row (9)

11

0.0 %

Type of Reporting Person (See Instructions)

12

IN

SCHEDULE 13G

CUSIP No. 05153U107

Names of Reporting Persons

1

Daniel Estes

2 Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

Beneficially

6

0.00

Owned by

Sole Dispositive Power

Each

7

0.00

Reporting

Person

With:

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

0.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.0 %

Type of Reporting Person (See Instructions)

12

IN

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Aura Biosciences, Inc.

Address of issuer's principal executive offices:

(b)

80 Guest Street, Boston, MA, 02135.

Item 2.

Name of person filing:

The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")

Address or principal business office or, if none, residence:

(b)

The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304

Citizenship:

(c)

The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.

(d) Title of class of securities:

Common Stock, \$0.00001 par value per share

CUSIP No.:

(e)

05153U107

Item 3. If this statement is filed pursuant to \hat{A} § 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 3,113,550 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLSPOF directly holds 918,510 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS X directly holds 128,520 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. FLS XI directly holds 342,210 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS XII directly holds 597,210 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 778,388 shares of Common Stock, (ii) FLSPOF holds Warrants to purchase 229,628 shares of Common Stock, (iii) FLS X holds Warrants to purchase 32,130 shares of Common Stock, (iv) FLS XI holds Warrants to purchase 85,552 shares of Common Stock and (v) FLS XII holds Warrants to purchase 149,302 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.

(b) Percent of class:

The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.

Date: 08/14/2025

FHMLSP, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.

Date: 08/14/2025

FHMLSP, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C.

Date: 08/14/2025

Frazier Life Sciences Public Overage Fund, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP Overage,
L.L.C., GP of FHMLSP Overage, L.P., GP of
Frazier Life Sciences Public Overage Fund, L.P.

Date: 08/14/2025

FHMLSP Overage, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP Overage,
L.L.C., GP of FHMLSP Overage, L.P.

Date: 08/14/2025

FHMLSP Overage, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP Overage,
L.L.C.

Date: 08/14/2025

Frazier Life Sciences X, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C.,
GP of FHMLS X, L.P., GP of Frazier Life
Sciences X, L.P.

Date: 08/14/2025

FHMLS X, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C.,
GP of FHMLS X, L.P.

Date: 08/14/2025

FHMLS X, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C.

Date: 08/14/2025

Frazier Life Sciences XI, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,
GP of FHMLS XI, L.P., GP of Frazier Life
Sciences XI, L.P.

Date: 08/14/2025

FHMLS XI, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,
GP of FHMLS XI, L.P.

Date: 08/14/2025

FHMLS XI, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.

Date: 08/14/2025

Frazier Life Sciences XII, L.P.

Signature: /s/ Gordon Empey

Name/Title: By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.

Date: 08/14/2025

FHMLS XII, L.P.

Signature: /s/ Gordon Empey

Name/Title: By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.

Date: 08/14/2025

FHMLS XII, L.L.C.

Signature: /s/ Gordon Empey

Name/Title: By Gordon Empey, General Counsel of FHMLS XII, L.L.C.

Date: 08/14/2025

James N. Topper

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017

Date: 08/14/2025

Patrick J. Heron

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017

Date: 08/14/2025

Albert Cha

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

Date: 08/14/2025

James Brush

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

Date: 08/14/2025

Daniel Estes

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022

Date: 08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of May 23, 2025, incorporated by reference into this Statement.